Serve as the primary strategic cybersecurity partner to the Rare Disease Unit (RDU) IT organization and associated business areas, representing the CISO by leading cybersecurity engagement, alignment, and delivery of cybersecurity risk and resilience outcomes across AstraZeneca’s rare disease research, clinical development, regulatory, and commercial activities. This customer-facing role will be closely coupled with the RDU IT leadership team and operate as a dotted-line function to the RDU IT VP, supporting the science, technology, and data capabilities that underpin discovery research, translational science, clinical trials, and patient-centered therapy development for rare diseases.
The role provides strategic guidance on cybersecurity risks, priorities, and long-term security posture across the rare disease therapeutic lifecycle and associated technology estate, including research and laboratory informatics, clinical trial systems, electronic data capture, clinical data management, regulatory submission platforms, scientific computing environments,



bioinformatics and genomics platforms, real-world data assets, and patient registries. A central focus is enabling RDU to adopt and scale secure-by-design, secure-by-default, and policy-aligned scientific and operational practices while maintaining research velocity, data integrity, system validation, patient safety, and compliance with AstraZeneca’s Security Policy Framework and applicable regulatory obligations (including GxP , GMP, GLP, GCP, 21 CFR Part 11, HIPAA, and GDPR).
This leader will direct a dedicated team with functional areas including cybersecurity posture reporting and data analysis, risk management and remediation, and security consulting—specifically tailored to the rare disease research, clinical, and commercial functions described. The role will help shape secure scientific and clinical technology patterns, strengthen cyber governance for research, clinical, and regulatory technology decisions, and

📌 Biso - Rdu (Laza)
🏢 AstraZeneca
📍 Laza